The impacted products have now been given a Class I risk classification by the U.S. Food and Drug Administration.
Trump's staff is laying the groundwork to prepare for a new FDA commissioner and make their mark at the agency.
In October, the FDA in collaboration with the U.S. Customs and Border Protection (CBP), seized about three million units of ...
Olympus advised providers to stop using an endoscope accessory due to an infection risk linked to 120 injuries and one death.
A discussion of the development of consumer protection law in the US through the enactment of key legislation and formation ...
With Donald Trump taking office and Robert F. Kennedy Jr. poised to assume the nation’s top health role, it seems the agency ...
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in metastatic ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
The FDA is expected to decide on treatments for Parkinson disease, PTSD and NF1-associated plexiform neurofibromas, in addition to 2 new vaccines.